Introduction
============

In less developed countries, liver cancer was the second leading cause of cancer-related deaths worldwide in the male population [@B1]. It was estimated that roughly 782,500 cases of new liver cancer and 745,500 deaths occurred in 2012, with China accounting for 50% of all the new cases and deaths [@B1]. Hepatocellular carcinoma (HCC) accounted for 70% to 90% of primary liver cancers worldwide [@B2]. Aetiologically, many factors, such as dietary aflatoxin exposure, alcohol consumption [@B3], hepatitis B virus (HBV) infection, hepatitis C virus infection, diabetes mellitus, obesity [@B4] and cirrhosis [@B5], had been reported to be associated with the development of HCC. Meanwhile, many treatments had been applied, such as radical hepatectomy, liver transplantation, percutaneous ethanol injection, radiofrequency ablation and transarterial chemoembolisation [@B5]. Even with these advances, the prognosis of HCC patients remained poor, with the 5-year survival rate less than 15% [@B6], [@B7]. Currently, the diagnosis of HCC had relied on α-fetoprotein (AFP) levels. However, the sensitivity and specificity of AFP levels were not sufficient for HCC diagnosis, as patients with cirrhosis and chronic hepatitis could show elevated AFP levels [@B8]. Therefore, it was of significance to identify new biomarkers for the early diagnosis of HCC.

Human Leukocyte Antigen (HLA) complex, \~4Mb and on chromosome 6 p21 in humans, is composed of *HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB6, HLA-E, HLA-F* and *HLA-G*. HLA plays a key role in antigen presentation to T cells and the basic formation of host defence mechanisms against pathogens [@B9], [@B10]. HLA, encoding major histocompatibility complex (MHC), is also important in vaccine development and has a determining role in transplantation outcomes [@B11]. Members of this complex have been investigated for disease initiation and progression. A good clinical outcome is associated with high-solution HLA-matching in haematopoietic stem cell transplantation [@B12], [@B13]. *HAL-B* Bw4-80lle, combined with the *KIR3DS1* gene, can significantly affect outcomes of chronic hepatitis B patients who were treated with alpha interferon [@B14]. It had been documented that *HLA-G*, a nonclassical HLA class I molecule, positivity was related to the disease in breast cancer, renal cell carcinoma, lung cancer and malignant melanoma, also indicating differential expressions in lobular and ductal subtypes [@B15]. *HLA-G* played a pivotal function in maternal-foetal tolerance during pregnancy [@B16], and aberrant expression of *HLA-G* was observed in multiple malignant cell types, which might be related to the procedure of escape host immunosurveillance [@B17]. *HLA-DRB1\*01* had been observed to be associated with hepatic hypersensitivity reactions [@B18]. Given previous studies on members of the HLA complex with tumours, we, therefore, conducted an investigation that aimed to find relationship a between the HLA complex and HCC.

Materials and Methods
=====================

Data collection
---------------

Profiling data of the GSE14520 dataset was obtained from the Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse14520>, accessed May 5, 2018) website. This dataset contains two platforms: GPL571 (Affymetrix Human Genome U133A 2.0 Array) and GPL3921 (Affymetrix HT Human Genome U133A Array) [@B19], [@B20]. Only GPL3921 data were used in our study to avoid batch effect. Patients with HBV infection were included in the present study.

Expression collection of HLA family genes
-----------------------------------------

Transcription, interactive bodymap and gene expression levels were collected from Gene Expression Profiling Interactive Analysis (GEPIA, <http://gepia.cancer-pku.cn/index.html>, accessed May 6, 2018) [@B21]. Protein expressions of HLA family genes were collected from The Human Protein Atlas (<https://www.proteinatlas.org/>, accessed accessed May 6, 2018) website [@B22].

Gene set enrichment analysis
----------------------------

Gene set enrichment analysis (GSEA) was performed to obtain biological processes and metabolic pathways of HLA family genes at the transcriptional level. Datasets of c2.cp.kegg.v6.1.symbols.gmt, c5.bp.b6.1.symbols.gmt, c5.cc.v6.1.symbols.gmt and c5.mf.v6.1.symbols.gmt were utilised to analyse significant gene ontology (GO), including biological process (BP), cellular component (CC), molecular function (MF) and metabolic pathway [@B23], [@B24].

Association and interaction analysis
------------------------------------

Pearson correlation analysis among HLA family genes was performed using R version 3.5.0 (<https://www.r-project.org/>). A co-expression interactive network of gene-gene was constructed using the geneMANIA plugin of Cytoscape software version 3.6.0 [@B25], [@B26]. A protein-protein interaction (PPI) network was constructed using STRING (<https://string-db.org/cgi/input.pl>, accessed May 8, 2018) website [@B27]. Visualised enrichment analysis of GO was conducted using the BiNGO plugin of Cytoscape software version 3.6.0 [@B28].

Diagnostic and survival analysis
--------------------------------

Overall survival (OS) and recurrence-free survival (RFS) were calculated using Kaplan-Meier and Cox proportional hazards regression models. Gene expressions were categorised into low expression and high expression groups at a cut-off of median expression level. Statistically significant factors were adjusted for survival analysis. OS and RFS-related genes were further analysed for joint-analysis. Validation of prognostic values of HLA family genes were further conducted in the Kaplan-Meier Plotter (<http://kmplot.com/analysis/>, accessed May 12, 2018) website [@B29].

Expression model and nomogram construction
------------------------------------------

To further explore prognosis-related genes in both univariate and multivariate analyses for HCC survival, we further constructed expression models for OS and RFS prediction. Nomograms were constructed using clinical factors and gene expressions. Different factors and gene expressions showed different points. Taken together, total points can predict HCC patient probability of survival at 1 year, 3 years and 5 years.

Stratified and joint-effect analysis
------------------------------------

Prognosis (OS and RFS)-related genes were further stratified for analysis in clinical factors. Genes related to OS and RFS in the multivariate analysis were further stratified for analysis with demographic and clinical factors. In addition, prognosis (OS and RFS)-related genes were joined for combination analysis. Expressions that indicated a good prognosis were conferred a score of 1, whereas bad prognoses were conferred a score of 0.

Statistical analysis
--------------------

Survival analyses were performed using SPSS software version 16.0 (IBM, Chicago, IL). Median survival time (MST) and log-rank *P* were calculated by Kaplan-Meier method, as well as 95% confidence interval (CI) and hazard ratio (HR) were calculated by univariate and multivariate Cox proportional hazards regression models. Box plots and survival plots were obtained using GraphPad software version 7.0. *P* value ≤ 0.05 was statistically significant.

Results
=======

Demographic and clinical characteristics of HCC patients
--------------------------------------------------------

A total of 212 HBV-related HCC patients were included in the present study. Tumour size, cirrhosis, AFP and BCLC stage showed significance in OS (*P* = 0.002, 0.041, 0.049 and \< 0.0001, respectively). Gender, cirrhosis and BCLC stage showed significance in RFS (*P* = 0.002, 0.036, and \< 0.0001, respectively). Other factors did not show significance (all *P* \> 0.05, **Supplementary Table [1](#SM0){ref-type="supplementary-material"}**).

Expression and transcription analysis
-------------------------------------

mRNA expression of HLA family members showed that *HLA-A, HLA-C, HLA-DMA, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB6* and *HLA-E* showed significance in the comparison between tumour and normal tissues (all *P* ≤ 0.05,**Figure [1](#F1){ref-type="fig"}A, C, E, H-K, M-Q**). However, other genes did not show significance (all *P* \> 0.05,**Figure [1](#F1){ref-type="fig"}B, D, F, G, L, R-S**). Protein expression showed that all of the HLA family members had low levels of expression in the liver, except HLA-A, HLA-C, HLA-DQB2, HLA-DRB4, HLA-DRB6 and HLA-F did show in the Human Protein Atlas website (**Supplementary Figure [1](#SM0){ref-type="supplementary-material"}**). A bodymap of HLA family members in human organs was shown in **Supplementary Figure [2](#SM0){ref-type="supplementary-material"}**. Transcriptional analysis indicated that all the members consistently showed higher transcripts per millions in tumour tissues compared with normal tissues (**Figure [2](#F2){ref-type="fig"}**).

Diagnostic and prognostic analysis
----------------------------------

In the diagnostic analysis of the HLA family, *HLA-A, HLA-C, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB6* and *HLA-E* showed significance for HCC diagnosis (all *P* ≤ 0.05, **Figure [3](#F3){ref-type="fig"}A, C, E-K, M-Q**). HLA-C showed the highest area under curve (AUC, 0.784).

In the univariate OS analysis, only *HLA-DPB1* and *HLA-F* showed significance (crude *P* = 0.039 and 0.043, respectively; **Table [1](#T1){ref-type="table"}**, **Figure [4](#F4){ref-type="fig"}H, R**). In the multivariate OS analysis, *HLA-DQA1* and *HLA-F* showed significance (adjusted *P* = 0.012 and 0.014, **Table [1](#T1){ref-type="table"}**). In the univariate RFS analysis, only *HLA-C* showed significance (crude *P* = 0.022; **Table [2](#T2){ref-type="table"}**, **Figure [5](#F5){ref-type="fig"}C**). In the multivariate RFS analysis, *HLA-A, HLA-C, HLA-DPA1* and *HLA-DQA1* showed significance (adjusted *P* = 0.019, 0.031, 0.040 and 0.030, respectively; **Table [2](#T2){ref-type="table"}**).

Joint-effect analysis and stratified analysis
---------------------------------------------

Expressions that indicated a good prognosis were conferred a score of 1, whereas bad prognosis was conferred a score of 0. In the joint-effect analysis of OS, the 2 scores group exhibited significant *P* value compared with the 0 score group (adjusted *P* = 0.001, **Table [3](#T3){ref-type="table"}**). In the joint-effect analysis of RFS, the 2 scores group exhibited significant *P* value compared with the 0 score group (adjusted *P* = 0.001, **Table [3](#T3){ref-type="table"}**). Groups of 2 scores, 3 scores and 4 scores showed significance compared with the 0 score group (adjusted *P* = 0.005, 0.012 and \< 0.001, respectively).

In the stratification of *HLA-DQA1* for OS analysis, high expression showed significance in males, age ≤ 60 years, active viral replication-chronic carriers of HBV, cirrhosis, single nodular, low AFP levels (≤ 300 ng/ml) and A stage of the BCLC system compared with low expression (**Table [4](#T4){ref-type="table"}**). In the stratification of *HLA-A* for RFS analysis, high expression showed significance in males, age \> 60 years, chronic HBV carriers, tumour size \> 5 cm, cirrhosis, low AFP levels (≤ 300 ng/ml) and C stage of the BCLC system compared with low expression. Detailed results of the stratified analysis were shown in **Table [4](#T4){ref-type="table"}** and**5**.

Expression model and nomogram construction
------------------------------------------

Expression models were constructed for OS and RFS prognosis in **Figure [6](#F6){ref-type="fig"}** and**7**, respectively. Expressions, survival statuses and heatmaps were shown in **Figure [6](#F6){ref-type="fig"}A** and**7A**. Prognostic receiver operating characteristic (ROC) curves were shown in **Figure [6](#F6){ref-type="fig"}B** and**7B** (*P* = 0.041 and 0.021, respectively). AUCs at 1 year, 3 years and 5 years were 0.862, 0.942 and 0.993, respectively, in the OS risk score model and 0.511, 0.533 and 0.568, respectively, in the RFS risk score model.

In addition, clinical factors and prognosis-related genes were further constructed in nomograms. High expression levels always led to low points. The same points indicated a highest probability of survival at 1 year and a lowest probability of survival at 5 years. Survival probability at 3 years was seated in the middle (**Figure [8](#F8){ref-type="fig"}**).

GSEA analysis
-------------

GSEA results of the OS-related gene *HLA-F* indicated that GO and pathways were involved in positive regulation of the immune response, leukocyte cell-cell adhesion, chemokine signalling pathway and focal adhesion (**Figure [9](#F9){ref-type="fig"}A, D, M-N**). GSEA results of the RFS-related gene *HLA-A* indicated that GO and pathways were involved in antigen processing and presentation of peptide antigens via MHC class I, cell defence response, autoimmune thyroid disease and toll like receptor signalling pathway (**Figure [10](#F10){ref-type="fig"}A, D, N-O**). Detailed GSEA results were shown in **Figure [9](#F9){ref-type="fig"}** and**10** and**Supplementary Figure [3](#SM0){ref-type="supplementary-material"}-5**.

Interaction and co-expression networks and enrichment analysis
--------------------------------------------------------------

Comparison between low and high levels of expression were shown in**Figure [11](#F11){ref-type="fig"}A** and **B**. Significant *P* values were exhibited in all HLA family members (all *P* ≤ 0.05). Matrices showed Pearson correlations among HLA members (**Figure [11](#F11){ref-type="fig"}C**). Co-expression interaction and PPI networks showed relationships among HLA members (**Figure [11](#F11){ref-type="fig"}D and E**).

The top 10 GO terms and KEGG pathways were exhibited in**Figure [12](#F12){ref-type="fig"}**. Detailed GO terms and KEGG pathways were shown in**Supplementary Table [1](#SM0){ref-type="supplementary-material"}**. Visualised interactions of GO terms constructed using BiNGO were shown in**Supplementary Figure [6](#SM0){ref-type="supplementary-material"}.**

Validation of prognostic values of HLA family members
-----------------------------------------------------

Prognostic values of HLA family members were further validated in the whole population. *HLA-C, HLA-DPA1, HLA-E, HLA-F* and*HLA-G* showed significance in OS (all *P* ≤ 0.05, **Figure [13](#F13){ref-type="fig"}C, H, P-R**). However, other genes did not show significance (all *P* \> 0.05,**Figure [13](#F13){ref-type="fig"}**).

Discussion
==========

In the present study, we conducted an investigation on the relationships between the HLA complex and HBV-related HCC patients. We found that members of the HLA complex, *HLA-A, HLA-C, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB6* and *HLA-E*, showed significant diagnostic values for HCC. Among them, *HLA-C* showed the highest diagnostic value. In addition, *HLA-DQA1* and*HLA-F* showed prognostic values for OS, and *HLA-A, HLA-C, HLA-DPA1* and *HLA-DQA1* showed prognostic values for RFS. Then, joint-effect and stratified analyses were explored the prognostic values of all the prognosis-related genes. GSEA found that they were involved in positive regulation of the immune response, antigen processing and presentation of peptide antigens via MHC class I, chemokine signalling pathway, focal adhesion and toll like receptor signalling pathway. Risk score models and nomograms were constructed to evaluate HCC prognosis. Further validation of prognosis-related genes in the Kaplan-Meier Plotter website indicated that *HLA-C, HLA-DPA1, HLA-E, HLA-F* and *HLA*-G were associated with HCC prognosis in OS. Therefore, we concluded that *HLA-C, HLA-DPA1* and*HLA-F* gene expression were associated with HCC prognosis, and *HLA-A* and *HLA-DQA1* gene expression were associated with prognosis of HBV-related HCC. *HLA-C* had diagnostic value for HCC, and*HLA-A, HLA-C, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB6* and*HLA*-E had potentially diagnostic values for HCC.

The MHC complex, also known as the HLA in humans, consists of more than 200 genes on chromosome 6 and can be categorised into three groups: class I, class II and class III [@B30]. Class I, which is characterised by CD8+ T cells, is composed of three genes: *HLA-A, HLA-B* and*HLA-C* [@B30]. Class II, which is characterised by CD4+ T cells, is composed of six main genes: *HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA* and*HLA-DRB1* [@B30]. HLA genes were documented as numerous and highly polymorphic in order to bind many kinds of peptides originating from self or foreign antigens [@B30]. More than 1500 alleles of the *HLA-B* gene had been identified [@B31]. Variants of the HLA complex played a pivotal role in determining the susceptibility to autoimmune diseases and infections [@B32]. Meanwhile, they were crucial in the field of transplantation surgery, where HLA-matching compatibility was a precondition in the donors and recipients [@B32]. An association between the presence of *HLA-B*\*57:01 alleles and abacavir hypersensitivity was observed in Australian and British cohorts [@B33], [@B34]. Genome-wide association studies showed that the *HAL-A* \*31:01 allele had a strong association with carbamazepine-induced hypersensitivity in Northern Europeans, Japanese and Koreans (OR = 25.93, 10.8 and 7.3, respectively) [@B35]-[@B38].

Alterations of amino acids bringing in structural and functional dissimilarities between *HLA-DPB1* alleles revealed a strong median impact of alloreactive responses to these molecules [@B39]. It had been observed that a high frequency of the *HLA-DRB1*\*15:01-*DRB*5\*01:01-*DQB*1\*06:02 haplotype in patients with amoxicillin clavulanate-induced drug-induced liver injury compared with normal healthy controls (57.1% (case) versus 11.7% (controls), *P* \< 10^-6^). A study focusing on *HLA-DQB1* and *HLD-DRB1* in the Tunisian population revealed the involvement of rs6457617 locus as a risk variant for susceptibility/severity to rheumatoid arthritis and highlighted gene-gene interaction between the two genes [@B40].

Recently, many researches had been performed to investigate the relationships among initiation and progression of tumours and the HLA family. Single nucleotide polymorphisms of *HLA-A* and amino acid variants were associated with nasopharyngeal carcinoma in Malaysian Chinese [@B41]. *HLA-B*-associated transcript 3 polymorphisms were suggested as risk factors for lung cancer in a meta-analysis [@B42]. An association was observed between an increase in *HLA-C1/KIR2DL2* and *HLA-C1/KIRDL3* pairs and invasive cervical cancer patients at high-risk from human papillomavirus infection [@B43]. Hu et al. reported, for the first time, that genetic variants in the *HLA-DP/DQ* loci might be marker polymorphisms for both HBV infection and risk of developing HCC [@B44]. *HLA-DPB1* polymorphisms increased the risk for cervical squamous cell carcinoma in Taiwanese women [@B45].

*HLA-DQA1* gene copy number polymorphism was associated with gastric cancer susceptibility in the Chinese population [@B46]. Rs17879599 in the second exon of the *HLA-DRB1* gene had been suggested as an independent leading contributor to HCC risk in Han Chinese [@B47]. Expression of *HLA-E* and *HLA-G* were found differently upregulated in HCC tissues [@B48]. However, our present study found that *HLA-E* and *HLA-G* were found differently upregulated in non-HCC tissues, and a statistically significant difference was shown only in *HLA-E*.

To date, the HLA family had been widely explored with regard to their prognostic values in multiple tumours. However, associations between the HLA family and HCC had not been fully explored until now. We, for the first time, explored diagnostic and prognostic values among the HLA complex and HCC. HBV infection had widely been recognized as a risk factor for HCC. Two HLA-DRB1-*DQB1* haplotypes, such as *DRB1\*15:02-DQB1\*06:01* and *DRB1\*13:02-DQB1\*06:04*, and three DPB1 alleles, such as *DPB1\*02:01, \*04:02*, and *\*05:01*, were found associations with chronic HBV infection in Japanese population [@B49].

Dianwu Liu et al. suggested that thirty four variants of eight HLA genes, including *HLA-B, HLA-C, HLA-DPA1, HLA-DQA1, HLA-DQB1, HLA-DQB2, HLA-DRB1*, and *HLA-DRB5*, were strongly associated with HBV-related HCC [@B50]. Weiping Zhou et al. suggested that new associations at rs9272105 (*HLA-DQA1/DRB1*) on 6p21.32 (odds ratio=1.30, *P*=1.13E-19) [@B51]. This finding is consistent with our present study of association between *HLA-DQA1* and HCC.

Hyon-Suk Kim et al. found that serum level of soluble *HLA-G* (s*HLA-G*) was correlated with the progression of HBV infection [@B52]. In addition, AUC of s*HLA-G* for distinguishing HCC from liver cirrhosis was higher than that of AFP and would be a diagnostic biomarker for HCC [@B52]. Moreover, they indicated that s*HLA-G* should not to be considered as severity of HBV infections and HCC but rather reflects phases of diseases including HBV-related HCC and concluded that increased s*HLA-G* expression could be one of the immune escape mechanisms of both HBV infection and HCC [@B52]. Nonetheless, our present study did not find clinical significance of *HLA-G* for HCC. This contradiction might be attributed to the difference of study population and ethnicity.

There were some limitations in the present study that need to be recognised. First, larger population cohorts were warranted to further validate our findings. Second, multivariate analyses were needed to generalise our results, a HBV-related HCC cohort. Third, functional trials were needed in future studies to explore the properties of prognosis-related genes in tumour proliferation, metastasis and angiogenesis.

Conclusions
===========

In the present study, we conducted investigations for associations between the HLA complex and HCC. We found that some genes had diagnostic values for HCC. Among them, HLA-C was the most diagnostic biomarker for HCC. In addition, *HLA-DQA1* and*HLA-F* had prognostic values for OS, whereas *HLA-A, HLA-C, HLA-DPA1* and *HLA-DQA1* had prognostic values for RFS. GSEA found they were involved in positive regulation of the immune response, antigen processing, chemokine signalling pathway and toll like receptor signalling pathway. Risk score models and nomograms were used to evaluate values of prognosis-related genes for HCC. Further validation in the Kaplan-Meier Plotter website indicated that *HLA-C, HLA-DPA1, HLA-E, HLA-F* and *HLA*-G were associated with HCC prognosis in OS. Therefore, we concluded that *HLA-C, HLA-DPA1* and*HLA-F* expression were associated with HCC prognosis, and *HLA-A* and *HLA-DQA1* gene expression were associated with prognosis of HBV-related HCC. *HLA-C* might be a diagnostic biomarker for HCC.
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###### 

Overall survival analysis of HLA family genes

  Variables               Overall survival                                                                           
  ----------------- ----- ------------------ ------- ------------------------- ----------- ------------------------- -----------
  *HLA-A*                                                                                                            
  Low expression    106   43                 NA      Ref.                                  Ref.                      
  High expression   106   39                 NA      0.824 (0.534-1.271)       0.382       0.730 (0.468-1.139)       0.166
  *HLA-B*                                                                                                            
  Low expression    106   43                 NA      Ref.                                  Ref.                      
  High expression   106   39                 NA      0.921 (0.597-1.421)       0.711       1.016 (0.657-1.573)       0.942
  *HLA-C*                                                                                                            
  Low expression    106   45                 NA      Ref.                                  Ref.                      
  High expression   106   37                 NA      0.770 (0.498-1.190)       0.239       0.736 (0.474-1.141)       0.170
  *HLA-DMA*                                                                                                          
  Low expression    106   44                 NA      Ref.                                  Ref.                      
  High expression   106   38                 NA      0.809 (0.524-1.249)       0.339       0.785 (0.508-1.215)       0.278
  *HLA-DMB*                                                                                                          
  Low expression    106   38                 NA      Ref.                                  Ref.                      
  High expression   106   44                 NA      1.204 (0.780-1.859)       0.401       1.173 (0.745-1.845)       0.491
  *HLA-DOA*                                                                                                          
  Low expression    106   43                 NA      Ref.                                  Ref.                      
  High expression   106   39                 NA      0.923 (0.598-1.423)       0.716       0.997 (0.636-1.562)       0.988
  *HLA-DOB*                                                                                                          
  Low expression    106   37                 NA      Ref.                                  Ref.                      
  High expression   106   45                 NA      1.295 (0.838-2.001)       0.245       1.304 (0.837-2.030)       0.241
  *HLA-DPA1*                                                                                                         
  Low expression    106   38                 NA      Ref.                                  Ref.                      
  High expression   106   44                 NA      1.110 (0.719-1.713)       0.638       1.198 (0.766-1.874)       0.429
  *HLA-DPB1*                                                                                                         
  Low expression    106   35                 NA      Ref.                                  Ref.                      
  High expression   106   47                 60.50   **1.587 (1.024-2.460)**   **0.039**   1.566 (0.998-2.458)       0.051
  *HLA-DQA1*                                                                                                         
  Low expression    106   44                 NA      Ref.                                  Ref.                      
  High expression   106   38                 NA      0.846 (0.548-1.306)       0.449       **0.563 (0.359-0.883)**   **0.012**
  *HLA-DQB1*                                                                                                         
  Low expression    106   38                 NA      Ref.                                  Ref.                      
  High expression   106   44                 NA      1.222 (0.792-1.888)       0.365       1.393 (0.896-2.166)       0.141
  *HLA-DQB2*                                                                                                         
  Low expression    106   40                 NA      Ref.                                  Ref.                      
  High expression   106   42                 NA      1.012 (0.656-1.560)       0.957       0.968 (0.624-1.501)       0.884
  *HLA-DRA*                                                                                                          
  Low expression    106   42                 NA      Ref.                                  Ref.                      
  High expression   106   40                 NA      0.920 (0.596-1.418)       0.705       0.816 (0.523-1.272)       0.369
  *HLA-DRB1*                                                                                                         
  Low expression    106   42                 NA      Ref.                                  Ref.                      
  High expression   106   40                 NA      0.927 (0.601-1.430)       0.732       0.742 (0.468-1.177)       0.205
  *HLA-DRB4*                                                                                                         
  Low expression    106   44                 NA      Ref.                                  Ref.                      
  High expression   106   38                 NA      0.905 (0.586-1.398)       0.654       0.869 (0.562-1.345)       0.529
  *HLA-DRB6*                                                                                                         
  Low expression    106   46                 NA      Ref.                                  Ref.                      
  High expression   106   36                 NA      0.738 (0.477-1.142)       0.173       0.893 (0.569-1.402)       0.624
  *HLA-E*                                                                                                            
  Low expression    106   42                 NA      Ref.                                  Ref.                      
  High expression   106   40                 NA      0.909 (0.589-1.402)       0.666       1.102 (0.691-1.755)       0.684
  *HLA-F*                                                                                                            
  Low expression    106   46                 NA      Ref.                                  **Ref.**                  
  High expression   106   36                 NA      **0.636 (0.411-0.985)**   **0.043**   **0.576 (0.371-0.896)**   **0.014**
  *HLA-G*                                                                                                            
  Low expression    106   40                 NA      Ref.                                  Ref.                      
  High expression   106   42                 NA      1.128 (0.731-1.739)       0.586       1.289 (0.830-2.003)       0.258

Note: ɸ: *P* values were adjusted for tumor size, cirrhosis, AFP and BCLC stage.

###### 

Recurrence-free survival analysis of HLA family genes

  Variables               Recurrence-free survival                                                                           
  ----------------- ----- -------------------------- ------- ------------------------- ----------- ------------------------- -----------
  *HLA-A*                                                                                                                    
  Low expression    106   61                         35.20   Ref.                                  Ref.                      
  High expression   106   55                         51.60   0.780 (0.542-1.123)       0.182       **0.638 (0.439-0.930)**   **0.019**
  *HLA-B*                                                                                                                    
  Low expression    106   58                         43.20   Ref.                                  Ref.                      
  High expression   106   58                         45.90   0.989 (0.687-1.424)       0.954       1.105 (0.764-1.598)       0.597
  *HLA-C*                                                                                                                    
  Low expression    106   67                         30.7    Ref.                                  Ref.                      
  High expression   106   49                         57.9    **0.649 (0.448-0.938)**   **0.022**   **0.664 (0.458-0.963)**   **0.031**
  *HLA-DMA*                                                                                                                  
  Low expression    106   61                         40.4    Ref.                                  Ref.                      
  High expression   106   55                         49.1    0.894 (0.621-1.287)       0.545       0.923 (0.640-1.332)       0.669
  *HLA-DMB*                                                                                                                  
  Low expression    106   52                         53.0    Ref.                                  Ref.                      
  High expression   106   64                         29.9    1.387 (0.962-2.001)       0.080       1.378 (0.943-2.015)       0.098
  *HLA-DOA*                                                                                                                  
  Low expression    106   60                         36.0    Ref.                                  Ref.                      
  High expression   106   56                         51.1    0.906 (0.629-1.305)       0.596       0.894 (0.617-1.294)       0.553
  *HLA-DOB*                                                                                                                  
  Low expression    106   56                         51.1    Ref.                                  Ref.                      
  High expression   106   60                         37.9    1.179 (0.819-1.697)       0.376       1.116 (0.772-1.615)       0.559
  *HLA-DPA1*                                                                                                                 
  Low expression    106   63                         36.6    Ref.                                  Ref.                      
  High expression   106   53                         53.3    0.795 (0.552-1.146)       0.219       **0.673 (0.462-0.982)**   **0.040**
  *HLA-DPB1*                                                                                                                 
  Low expression    106   57                         49.1    Ref.                                  Ref.                      
  High expression   106   59                         30.9    1.236 (0.858-1.779)       0.255       1.257 (0.860-1.837)       0.237
  *HLA-DQA1*                                                                                                                 
  Low expression    106   61                         40.4    Ref.                                  Ref.                      
  High expression   106   55                         53.3    0.887 (0.616-1.277)       0.518       **0.658 (0.451-0.960)**   **0.030**
  *HLA-DQB1*                                                                                                                 
  Low expression    106   61                         46.3    Ref.                                  Ref.                      
  High expression   106   55                         40.4    0.948 (0.658-1.365)       0.772       1.009 (0.699-1.458)       0.960
  *HLA-DQB2*                                                                                                                 
  Low expression    106   55                         46.3    Ref.                                  Ref.                      
  High expression   106   61                         37.9    1.164 (0.809-1.676)       0.413       1.202 (0.833-1.735)       0.324
  *HLA-DRA*                                                                                                                  
  Low expression    106   60                         37.9    Ref.                                  Ref.                      
  High expression   106   56                         51.1    0.851 (0.591-1.226)       0.386       0.786 (0.541-1.141)       0.206
  *HLA-DRB1*                                                                                                                 
  Low expression    106   57                         46.3    Ref.                                  Ref.                      
  High expression   106   59                         41.6    1.000 (0.695-1.440)       0.998       0.937 (0.635-1.380)       0.740
  *HLA-DRB4*                                                                                                                 
  Low expression    106   58                         32.7    Ref.                                  Ref.                      
  High expression   106   58                         49.1    0.992 (0.689-1.429)       0.967       0.952 (0.659-1.374)       0.793
  *HLA-DRB6*                                                                                                                 
  Low expression    106   59                         43.2    Ref.                                  Ref.                      
  High expression   106   57                         46.1    0.943 (0.655-1.357)       0.753       1.006 (0.696-1.453)       0.975
  *HLA-E*                                                                                                                    
  Low expression    106   57                         41.6    Ref.                                  Ref.                      
  High expression   106   59                         46.1    0.999 (0.694-1.439)       0.997       1.087 (0.745-1.585)       0.667
  *HLA-F*                                                                                                                    
  Low expression    106   62                         28.7    Ref.                                  Ref.                      
  High expression   106   54                         53.0    0.736 (0.511-1.061)       0.100       0.706 (0.488-1.021)       0.064
  *HLA-G*                                                                                                                    
  Low expression    106   60                         37.9    Ref.                                  Ref.                      
  High expression   106   56                         46.3    0.933 (0.648-1.343)       0.708       1.042 (0.717-1.514)       0.831

Note: Ѱ: *P* values were adjusted for gender, cirrhosis and BCLC stage.

###### 

Joint-effect analysis of prognostic-related genes for overall survival and recurrence-free survival

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category   Group   Score      Patients   MST    Crude HR\                 Crude *P* value   Adjusted HR\              Adjusted *P* value^ɸ^   Adjusted *P* value^Ѱ^
                                                  95%CI                                       95%CI                                             
  ---------- ------- ---------- ---------- ------ ------------------------- ----------------- ------------------------- ----------------------- -----------------------
  OS         I       0          51         57.9                             0.112                                       **0.002**               

             II      1 score    110        NA     0.873 (0.525-1.453)       0.602             0.856 (0.509-1.439)       0.558                   

             III     2 scores   51         NA     **0.503 (0.257-0.984)**   **0.045**         **0.311 (0.156-0.620)**   **0.001**               

  RFS        A       0          12         35.2                             **0.022**                                                           **\<0.001**

             B       1 score    59         21.5   1.275 (0.597-2.721)       0.530             **0.565 (0.243-1.317)**                           **0.186**

             C       2 scores   74         54.8   0.689 (0.320-1.485)       0.342             **0.297 (0.126-0.699)**                           **0.005**

             D       3 scores   51         53.3   0.783 (0.355-1.724)       0.543             **0.331 (0.140-0.783)**                           **0.012**

             E       4 scores   16         NA     0.394 (0.129-1.204)       0.102             **0.107 (0.032-0.359)**                           **\<0.001**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

(**Note:** ɸ: *P* values in overall survival were adjusted for tumor size, cirrhosis, AFP and BCLC stage. *P* values in recurrence-free survival were adjusted for gender, cirrhosis and BCLC stage. **Scores in overall survival**: 0: Low *HLA-DQA1* + Low *HLA-F* expression; 1 score: Low *HLA-DQA1* + High *HLA-F* expression, High *HLA-DQA1* + Low *HLA-F* expression; 2 scores: High *HLA-DQA1* + High *HLA-F* expression. **Scores in disease-free survival**: 0: Low *HLA-A* + Low *HLA-C* + Low *HLA-DPA1* + Low *HLA-DQA1* expression; 1 score: High *HLA-A* + Low *HLA-C* + Low *HLA-DPA1* + Low*HLA-DQA1* expression, Low *HLA-A* + High *HLA-C* + Low *HLA-DPA1* + Low *HLA-DQA1* expression, Low *HLA-A* + Low *HLA-C* + High *HLA-DPA1* + Low *HLA-DQA1* expression, Low *HLA-A* + Low *HLA-C* + Low *HLA-DPA1* + High *HLA-DQA1* expression; 2 scores: High *HLA-A* + High *HLA-C* + Low *HLA-DPA1* + Low *HLA-DQA1* expression, High *HLA-A* + Low *HLA-C* + High *HLA-DPA1* + Low *HLA-DQA1* expression, High *HLA-A* + Low *HLA-C* + Low *HLA-DPA1* + High *HLA-DQA1* expression, Low *HLA-A* + High*HLA-C* + High *HLA-DPA1* + Low *HLA-DQA1* expression, Low *HLA-A* + High *HLA-C* + Low *HLA-DPA1* + High *HLA-DQA1* expression, Low *HLA-A* + Low *HLA-C* + High *HLA-DPA1* + High *HLA-DQA1* expression; 3 scores: High*HLA-A* + High *HLA-C* + High *HLA-DPA1* + Low *HLA-DQA1* expression, High *HLA-A* + High *HLA-C* + Low *HLA-DPA1* + High *HLA-DQA1* expression, High*HLA-A* + Low *HLA-C* + High *HLA-DPA1* + High *HLA-DQA1* expression, Low *HLA-A* + High *HLA-C* + High *HLA-DPA1* + High *HLA-DQA1* expression; 4 scores: High*HLA-A* + High *HLA-C* + High *HLA-DPA1* + High *HLA-DQA1* expression.)

###### 

Stratified analysis of prognostic-related genes for overall survival

  Variables      *HLA-DQA1*   *HLA-F*                                                                                   
  -------------- ------------ --------- ---------------------------- ----------- ---- ---- ---------------------------- -----------
  Gender                                                                                                                
  Male           88           95        **0.507 (0.315-0.814)**      **0.005**   91   92   **0.612 (0.386-0.971)**      **0.037**
  Female         18           11        11.866 (0.919-153.153)       0.058       15   14   0.139 (0.014-1.409)          0.095
  Age                                                                                                                   
  ≤60 years      89           86        **0.535 (0.326-0.878)**      **0.013**   90   85   **0.579 (0.357-0.937)**      **0.026**
  \>60 years     17           20        0.939 (0.295-2.987)          0.915       16   21   0.485 (0.129-1.832)          0.286
  HBV status                                                                                                            
  AVR-CC         30           26        **0.360 (0.130-0.993)**      **0.049**   26   30   0.615 (0.254-1.488)          0.281
  CC             76           80        0.687 (0.399-1.182)          0.175       80   76   **0.530 (0.306-0.917)**      **0.023**
  Tumor size                                                                                                            
  ≤5 cm          72           65        0.591 (0.311-1.123)          0.108       62   75   0.652 (0.360-1.179)          0.157
  \>5 cm         34           40        0.550 (0.279-1.086)          0.085       43   31   0.509 (0.251-1.032)          0.061
  Cirrhosis                                                                                                             
  Yes            91           104       **0.567 (0.361-0.890)**      **0.014**   97   98   **0.595 (0.381-0.929)**      **0.022**
  No             15           2         0.287 (2.599E-19-3.176E17)   0.953       9    8    0.002 (8.086E-22-4.683E15)   0.773
  Multinodular                                                                                                          
  Yes            18           27        0.719 (0.290-1.780)          0.476       21   24   **0.307 (0.122-0.772)**      **0.012**
  No             88           79        **0.503 (0.293-0.864)**      **0.013**   85   82   0.631 (0.373-1.069)          0.087
  AFP                                                                                                                   
  ≤300 ng/ml     59           56        **0.432 (0.217-0.861)**      **0.017**   54   61   0.857 (0.450-1.631)          0.639
  \>300 ng/ml    44           50        0.716 (0.390-1.315)          0.282       50   44   **0.433 (0.227-0.824)**      **0.011**
  BCLC stage                                                                                                            
  0              13           7         3.055 (0.190-49.157)         0.431       8    12   0.404 (0.024-6.735)          0.528
  A              75           68        **0.437 (0.240-0.796)**      **0.007**   74   69   0.616 (0.343-1.108)          0.106
  B              8            14        0.462 (0.110-1.933)          0.290       11   11   **0.109 (0.021-0.566)**      **0.008**
  C              10           17        1.381 (0.489-3.902)          0.542       13   14   0.800 (0.310-2.061)          0.644

Note: ɸ: *P* values were adjusted for tumor size, cirrhosis, AFP and BCLC stage.

###### 

Stratified analysis of prognostic-related genes for recurrence-free survival

  -------------- ------------ --------------------- -------------------------------- ----------- ------ --------------------- ------------------------- -----------
  Variables      *HLA-A*      *HLA-C*                                                                                                                   

  Low            High         Adjusted HR (95%CI)   Adjusted *P* value               Low         High   Adjusted HR (95%CI)   Adjusted *P* value        

  Gender                                                                                                                                                

  Male           89           94                    **0.567 (0.383-0.839)**          **0.005**   96     87                    **0.660 (0.447-0.974)**   **0.036**

  Female         17           12                    1.491 (0.321-6.921)              0.610       10     19                    0.541 (0.116-2.515)       0.433

  Age                                                                                                                                                   

  ≤60 years      86           89                    0.710 (0.470-1.074)              0.105       91     84                    0.675 (0.448-1.017)       0.060

  \>60 years     20           17                    **0.377 (0.148-0.958)**          **0.040**   15     22                    0.674 (0.270-1.680)       0.397

  HBV status                                                                                                                                            

  AVR-CC         29           27                    0.817 (0.408-1.634)              0.567       23     33                    **0.469 (0.234-0.940)**   **0.033**

  CC             77           79                    **0.610 (0.386-0.964)**          **0.034**   83     73                    0.664 (0.422-1.044)       0.664

  Tumor size                                                                                                                                            

  ≤5 cm          70           67                    0.844 (0.529-1.348)              0.478       67     70                    **0.554 (0.345-0.889)**   **0.014**

  \>5 cm         35           39                    **0.391 (0.208-0.735)**          **0.004**   38     36                    0.791 (0.418-1.495)       0.470

  Cirrhosis                                                                                                                                             

  Yes            97           98                    **0.643 (0.439-0.943)**          **0.024**   96     99                    0.694 (0.475-1.014)       0.059

  No             9            8                     1.356 (0.222-8.267)              0.741       10     7                     0.576 (0.061-5.460)       0.631

  Multinodular                                                                                                                                          

  Yes            20           25                    0.559 (0.232-1.347)              0.195       24     21                    0.567 (0.236-1.363)       0.205

  No             86           81                    0.679 (0.445-1.036)              0.072       82     85                    **0.582 (0.371-0.914)**   **0.019**

  AFP                                                                                                                                                   

  ≤300 ng/ml     51           64                    **0.580 (0.346-0.973)**          **0.039**   57     58                    0.673 (0.405-1.119)       0.127

  \>300 ng/ml    54           40                    0.709 (0.400-1.258)              0.240       48     46                    0.629 (0.361-1.097)       0.103

  BCLC stage                                                                                                                                            

  0              9            11                    2.624E5 (8.254E-158-8.340E167)   0.948       9      11                    0.402 (0.042-3.877)       0.431

  A              73           70                    0.662 (0.416-1.051)              0.080       72     71                    0.663 (0.416-1.057)       0.084

  B              11           11                    0.853 (0.259-2.811)              0.794       11     11                    0.599 (0.198-1.813)       0.364

  C              13           14                    **0.261 (0.096-0.709)**          **0.008**   14     13                    0.848 (0.346-2.079)       0.719

                                                                                                                                                        

  Variables      *HLA-DPA1*   *HLA-DQA1*                                                                                                                

  Low            High         Adjusted HR\          Adjusted\                        Low         High   Adjusted HR\          Adjusted\                 
                              (95%CI)               *P* value                                           (95%CI)               *P* value                 

  Gender                                                                                                                                                

  Male           91           92                    0.724 (0.489-1.072)              0.107       88     95                    **0.603 (0.407-0.893)**   **0.012**

  Female         15           14                    0.249 (0.050-1.238)              0.089       18     11                    1.978 (0.379-10.320)      0.418

  Age                                                                                                                                                   

  ≤60 years      86           89                    0.723 (0.479-1.090)              0.122       89     86                    **0.652 (0.430-0.989)**   **0.044**

  \>60 years     20           17                    0.445 (0.166-1.193)              0.108       17     20                    0.702 (0.281-1.753)       0.448

  HBV status                                                                                                                                            

  AVR-CC         28           28                    **0.377 (0.182-0.779)**          **0.008**   30     26                    **0.382 (0.174-0.840)**   **0.017**

  CC             78           78                    0.794 (0.503-1.255)              0.323       76     80                    0.739 (0.471-1.159)       0.188

  Tumor size                                                                                                                                            

  ≤5 cm          75           62                    0.658 (0.401-1.080)              0.098       72     65                    **0.607 (0.371-0.996)**   **0.048**

  \>5 cm         31           43                    0.788 (0.423-1.468)              0.453       34     40                    0.489 (0.358-1.325)       0.264

  Cirrhosis                                                                                                                                             

  Yes            95           100                   0.694 (0.472-1.020)              0.063       91     104                   **0.666 (0.455-0.973)**   **0.036**

  No             11           6                     0.563 (0.062-5.083)              0.609       15     2                     NA                        NA

  Multinodular                                                                                                                                          

  Yes            19           26                    1.318 (0.578-3.005)              0.511       18     27                    1.057 (0.466-2.401)       0.894

  No             87           80                    **0.562 (0.362-0.873)**          **0.010**   88     79                    **0.518 (0.331-0.812)**   **0.004**

  AFP                                                                                                                                                   

  ≤300 ng/ml     55           60                    0.744 (0.444-1.248)              0.263       59     56                    **0.585 (0.343-0.999)**   **0.050**

  \>300 ng/ml    48           46                    **0.540 (0.304-0.961)**          **0.036**   44     50                    0.692 (0.401-1.192)       0.184

  BCLC stage                                                                                                                                            

  0              13           7                     0.453 (0.050-4.104)              0.481       13     7                     1.165 (0.207-6.559)       0.862

  A              73           70                    0.649 (0.407-1.033)              0.069       75     68                    **0.050 (0.309-0.809)**   **0.005**

  B              12           10                    2.093 (0.674-6.498)              0.201       8      14                    1.165 (0.356-3.812)       0.801

  C              8            19                    0.717 (0.284-1.812)              0.482       10     17                    1.056 (0.420-2.655)       0.908
  -------------- ------------ --------------------- -------------------------------- ----------- ------ --------------------- ------------------------- -----------

Note: Ѱ: *P* values were adjusted for gender, cirrhosis and BCLC stage.
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